Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Patients With Motor Fluctuation in South Korea

NCT05312632 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT05312632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Patients With Motor Fluctuation in South Korea
Lead sponsor
Eisai Korea Inc.
Phase
Phase 4
Overall status
Completed
Start date
April 5, 2022
Completion date
May 25, 2023
Enrollment
201 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease